EU backs approval of Sanofi's diabetes and colorectal cancer drugs

11/19/2012 | CNBC · Bloomberg

A European Medicines Agency committee has recommended approval of Sanofi and Zealand Pharma's Lyxumia as a therapy for type 2 diabetes. Sanofi and Regeneron Pharmaceuticals' anti-angiogenic agent Zaltrap also won approval recommendation from the Committee for Medicinal Products for Human Use as a treatment for advanced colorectal cancer with chemotherapy.

View Full Article in:

CNBC · Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA